文献情報

  1. トップページ > 
  2. 文献情報
NEW
Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial.
Wataya-Kaneda M, et al. JAMA Dermatol. 2018; 154(7): 781-788
メール PubMed

NEW
Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial.
Wataya-Kaneda M, et al. JAMA Dermatol. 2017; 153(1): 39-48
メール PubMed

NEW
Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex.
Wataya-Kaneda M, et al. JAMA Dermatol. 2015; 151(7): 722-730
メール PubMed
Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus.
Nathan N, et al. J Am Acad Dermatol. 2015; 73(5): 802-808
メール PubMed

Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis.
Knöpfel N, et al. Actas Dermosifiliogr. 2014; 105(8): 802-803
メール PubMed

Successful treatment of subungual fibromas of tuberous sclerosis with topical rapamycin.
Muzic JG, et al. JAMA Dermatol. 2014; 150(9): 1024-1025
メール PubMed

A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex.
Wataya-Kaneda M, et al. Arch Dermatol. 2012; 148(1): 138-139
メール PubMed

Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient.
Micozkadioglu H, et al. Ren Fail. 2010; 32(10): 1233-1236
メール PubMed

Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
Tarasewicz A, et al. Transplant Proc. 2009; 41(9): 3677-3682
メール PubMed

Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model.
Rauktys A, et al. BMC Dermatol. 2008; 8 : 1.
メール PubMed

ページのトップへ

サイトマップ    個人情報保護基本方針    サイトポリシー    ご利用にあたって    会社概要

Copyright © Nobelpharma Co.,Ltd. all rights reserved.